RPG Life Sciences Q2 | Domestic Market Growth 16% vs Industry 7.9% | Ashok Nair | Business　 #ETNOW

RPG Life Sciences reports a strong Q2 FY26 performance with 16% domestic market growth, outperforming the market at 7.9%. Volume growth was 5.9%, price growth 2.9%, and new product contribution 5.9%. Key brands Naprocin grew 16.9%, MAPS 21%, and immunosuppressants 12.2%. API business faced a temporary setback due to a fire in January, resulting in a sales loss of ₹16 crore, but full restoration has been completed and commercial production resumes November–December. CAPEX of ₹45 crore for FY26 focuses on modernization and global audit readiness. H2 FY26 is expected to perform better than H1 with continued growth in domestic and API segments.

#rpglifesciences #pharmaearnings #q2fy26 #apibusiness #domesticgrowth #capexupdate #newproducts

control your money with economic times now.

YouTube Channel – https://www.youtube.com/@ETNow

Subscribe To ET Now For Latest Updates On Stocks Market News , Business News, Company News, IPO & More | https://bit.ly/SubscribeToETNow

Subscribe Now To Our Network Channels :-
ET Now Swadesh: https://www.youtube.com/etnowswadesh
Times Now: http://goo.gl/U9ibPb

Social Media Links :-
Twitter – http://goo.gl/hA0vDt
Facebook – http://goo.gl/5Lr4mC

Website – https://ift.tt/6qxhRI1